This educational activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia and the Management of Chronic Lymphocytic Leukemia Patients Treated With Immunotherapy
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center
This activity will provide advanced practitioners with up-to-date information on relapsed or refractory CLL to assist in clinical decision making, including the pathobiology at the core of Richter’s transformation. This session will also provide important information on emerging immunotherapies, which have added to the armamentarium in the treatment of CLL.
Management of Newly Diagnosed Chronic Lymphocytic Leukemia Patients
Supportive Care in Chronic Lymphocytic Leukemia
Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
What test should an advanced practitioner order if CLL is suspected?
What are the differences in the side effect profile between the monoclonal antibody treatments for CLL?
What are the most important prognostic factors in CLL?
How does Bruton's tyrosine kinase differ from other tyrosine kinases, and what role does it play in CLL and treatment?
The monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target CD20; how do they differ in their indications in the treatment of CLL?
What should advanced practitioners look for with CLL patients that also have lymphocytosis?
Bone Marrow Biopsy Demonstration Video